Novo Nordisk ZEUS Phase 3 failure sparks BIOA sympathy plunge
Novo Nordisk ZEUS Phase 3 failure sparks BIOA sympathy plunge on inflammation thesis doubts
- Novo's ziltivekimab (IL-6 inhibitor) lowered hsCRP as expected but showed no MACE benefit (HR 0.99).
- BIOA's BGE-102 (NLRP3 inhibitor) targets similar inflammation/CRP reduction for CV risk in ongoing Phase 2.
- Read-through hits inflammation hypothesis for CV outcomes, also pressuring peer $GLUE.
- No company-specific news from BioAge; pure sector sympathy in premarket.
- BIOA down ~52% premarket on 7/31/2026 after closing near $25 prior day.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.